An observational study in Osteoporotic Fracture of Femur and Osteoarthritis, Hip, sponsored by Istituto Ortopedico Rizzoli. Recruiting at 1 site in Italy. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Istituto Ortopedico Rizzoli · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Osteoarthritis, Hip by Istituto Ortopedico Rizzoli — 3 open to participants now, 3 under way, none of them phase 3. Osteoarthritis, Hip · Istituto Ortopedico Rizzoli.
Among the 13 studies in Osteoarthritis, Hip by Istituto Ortopedico Rizzoli, this one is the only one that started in 2020, is one of 4 observational ones, and was the 7th registered.
642 studies on the registry are indexed under Osteoarthritis, Hip; 120 are open to participants now.
Browse Osteoarthritis, Hip studies →3 of the 13 studies in Osteoarthritis, Hip by Istituto Ortopedico Rizzoli are open now, in 1 country. Recruiting first, the newest first:
Istituto Ortopedico Rizzoli · Sites in Italy
Ages 50–80
Istituto Ortopedico Rizzoli · Sites in Italy
Ages 35–70
By country, each count listing its studies:
Of the 86 Osteoarthritis, Hip studies recruiting now, 53 (62%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2020.
This study's planned enrollment of 100 is below the median of 135 across 158 observational studies indexed under Osteoarthritis, Hip.
Median enrollment 30 across the 9 interventional studies, 84 across the 4 observational. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
Istituto Ortopedico Rizzoli is the lead sponsor of 305 studies on the registry; 104 are open to participants now.
2 of the studies in Osteoarthritis, Hip by Istituto Ortopedico Rizzoli that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04730622Istituto Ortopedico RizzoliStudy of Parameters of Osteosarcopenia in Patients With Hip Fracture | 2026-12-31 |
| NCT06506201Istituto Ortopedico RizzoliLegs Dysmetria in Total Hip Replacement: Does Hip Approacches and Navigation Decrease the Risk? | 2027-05-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Osteoarthritis, Hip by Istituto Ortopedico Rizzoli, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study aims to assess the adequacy of a set of clinical and laboratory investigations for identifying the osteosarcopenia status in patients undergoing a hip replacement for a fragility fracture of the femoral neck. The control group will consist of patients undergoing a hip replacement for osteoarthritis, as the decrease in muscle function and bone quality is less severe in this condition than in osteoporosis.
Osteoporotic hip fractures (fragility fractures) are common in older adults, and the risk of adverse outcomes and mortality is higher in patients affected by osteosarcopenia, a geriatric syndrome in which the low bone mineral density and bone microarchitecture deterioration (osteopenia/osteoporosis) are combined with a decline in mass, strength, and functional capacity of skeletal muscle (sarcopenia).
The diagnostic workup currently recommended to establish the severity of osteosarcopenia is hard to implement in individuals who arrive at the orthopedic emergency department with a fragility fracture. On the one hand, the evaluation of motility and physical performance is impracticable in bedridden patients; on the other hand, the surgical treatment priority does not allow performing all the instrumental investigations required for a proper diagnosis. In this context, reliable osteosarcopenia biomarkers could help identify most frail patients and plan for them personalized therapeutic interventions to promote postoperative recovery and reduce the risk of adverse outcomes.
Based on the new knowledge on the pathophysiology of osteosarcopenia, the investigators designed a small-scale study that aims to preliminarily verify the adequacy of a set of clinical and laboratory parameters that could be easily applied in hospitalized patients undergoing hip replacement for a fragility fracture. In particular, the investigators planned to assess the following:
The study includes 100 patients who are candidates for hip replacement surgery (endo- and arthroplasty). As the decrease in muscle function and bone quality is more severe in fragility fractures than in osteoarthritis, the investigators expect to find differences in laboratory and clinical parameters.
Hospitalized patients admitted at the 1st Orthopaedic and Traumatology Unit of the Istituto Ortopedico Rizzoli (Bologna, Italy).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who are candidates for hip replacement surgery (endo- and arthroplasty).
Diagnostic Test: SARC-F questionnaire · Diagnostic Test: Bone tissue histology · Diagnostic Test: Muscle tissue histology · Diagnostic Test: Myostatin serum levels · Diagnostic Test: Insulin-like growth factor 1 (IGF-1) serum levels · Other: Frequency food questionnaire · Other: Gut microbiota profiling
Assessment of muscle performance based on self-reported information about grip strength, assistance with walking, rising from a chair, climbing stairs, and falls.
Assessment of histomorphology and matrix-structure of tissue samples obtained from the bone resected during the hip prosthesis positioning.
Assessment of histomorphology and ultrastructure of muscle biopsies taken from the upper portion of the vastus lateralis muscle, which is accessed in the surgical procedure of hip replacement.
Quantification of circulating myostatin, a muscle-specific biomarker that suppresses muscle growth and bone formation.
Quantification of circulating IGF-1, a growth factor that promotes muscle growth and osteogenesis.
Assessment of dietary habits based on self-reported information about the monthly- weekly- or daily-frequency consumption of main food groups, including cereals and bread, meat, fish, fruit, vegetable, legumes, dairy products, sweets and snacks, drinks, and dietary supplements.
Assessment of gut microbiome composition on stool samples.
Acceptability of the SARC-F questionnaire
The number of patients able to provide answers divided by the total number of enrolled patients.
Time frame: Within 24 hours of admission
Frequency of positive SARC-F questionnaire in cases (fragility fractures) and controls (osteoarthritis)
The percentage of cases (fragility fractures) and controls (osteoarthritis) who exhibit a positive SARC-F questionnaire. The SARC-F is positive and indicates potential sarcopenia if the score point is = or \> 4. For each component of the questionnaire (grip strength, assistance with walking, rising from a chair, climbing stairs, and falls), the score may be 0 (no difficulty; no falls), 1 (some difficulty), and 2 (a lot of difficulties and falls). The total score may range from 0 to 10.
Time frame: Within 24 hours of admission
Presence of histological features of osteoporotic bone in cases (fragility fractures) and controls (osteoarthritis)
The percentage of cases (fragility fractures) and controls (osteoarthritis) who exhibit histological features of osteoporotic bone. The presence of osteoporotic bone will be proved based on the following histological features: loss of connected trabecular bone, altered matrix mineralization, the prevalence of adipose tissue compared to bone marrow, presence of osteoclasts.
Time frame: Through study completion, an average of 1 year.
Presence of histological features of muscle atrophy in cases (fragility fractures) and controls (osteoarthritis)
The percentage of cases (fragility fractures) and controls (osteoarthritis) who exhibit histological features of muscle atrophy. The presence of muscle atrophy will be proved based on the following histological features: decrease in size and number of type II myofibers, presence of necrosis or fibro-adipose replacement, decrease in satellite cell number.
Time frame: Through study completion, an average of 1 year.
Myostatin serum levels in cases (fragility fractures) and controls (osteoarthritis)
The immunoenzymatic quantification of circulating Myostatin (µg/L) will be performed on serum samples obtained from peripheral venous blood. The results will be aggregated as mean ± standard error of the mean, median, and min-max range.
Time frame: Through study completion, an average of 1 year.
Insulin-like growth factor 1 (IGF-1) serum levels in cases (fragility fractures) and controls (osteoarthritis)
The immunoenzymatic quantification of circulating IGF-1 (µg/L) will be performed on serum samples obtained from peripheral venous blood. The results will be aggregated as mean ± standard error of the mean, median, and min-max range.
Time frame: Through study completion, an average of 1 year.
Acceptability of the Frequency Food Questionnaire
The number of patients able to provide answers divided by the total number of enrolled patients.
Time frame: Within 24 hours of admission
Frequency of intake of the different food categories in cases (fragility fractures) and controls (osteoarthritis)
The percentages of cases (fragility fractures) and controls (osteoarthritis) who assume never/rarely or regularly the different food categories.
Time frame: Within 24 hours of admission
Frequency of positive SARC-F questionnaire in patients with and without osteoporotic bone
The percentage of patients with and without osteoporotic bone who exhibit a positive (= or \> 4) or negative (\< 4) SARC-F questionnaire.
Time frame: Through study completion, an average of 1 year.
Frequency of positive SARC-F questionnaire in patients with and without muscle atrophy
The percentage of patients with and without muscle atrophy who exhibit a positive (= or \> 4) or negative (\< 4) SARC-F questionnaire.
Time frame: Through study completion, an average of 1 year.
Myostatin serum levels in patients with positive and negative SARC-F questionnaire
Mean ± standard error of the mean, median, and min-max range of circulating Myostatin (µg/L) in patients with positive (= or \> 4) and negative (\< 4) SARC-F questionnaire.
Time frame: Through study completion, an average of 1 year.
Myostatin serum levels in patients with and without osteoporotic bone
Mean ± standard error of the mean, median, and min-max range of circulating Myostatin (µg/L) in patients with and without osteoporotic bone.
Time frame: Through study completion, an average of 1 year.
Myostatin serum levels in patients with and without muscle atrophy
Mean ± standard error of the mean, median, and min-max range of circulating Myostatin (µg/L) in patients with and without muscle atrophy.
Time frame: Through study completion, an average of 1 year.
Insulin-like growth factor 1 (IGF-1) serum levels in patients with positive and negative SARC-F questionnaire
Mean ± standard error of the mean, median, and min-max range of circulating IGF-1 (µg/L) in patients with positive (= or \> 4) and negative (\< 4) SARC-F questionnaire.
Time frame: Through study completion, an average of 1 year.
Insulin-like growth factor 1 (IGF-1) serum levels in patients with and without osteoporotic bone
Mean ± standard error of the mean, median, and min-max range of circulating IGF-1 (µg/L) in patients with and without osteoporotic bone.
Time frame: Through study completion, an average of 1 year.
Insulin-like growth factor 1 (IGF-1) serum levels in patients with and without muscle atrophy
Mean ± standard error of the mean, median, and min-max range of circulating Myostatin (µg/L) in patients with and without muscle atrophy.
Time frame: Through study completion, an average of 1 year.
Frequency of intake of the different food categories in patients with positive and negative SARC-F questionnaire
The percentage of patients with positive (= or \> 4) and negative (\< 4) SARC-F questionnaire who assume never/rarely and regularly the different food categories.
Time frame: Within 24 hours of admission
Frequency of intake of the different food categories in patients with and without osteoporotic bone
The percentage of patients with and without osteoporotic bone who assume never/rarely and regularly the different food categories.
Time frame: Through study completion, an average of 1 year.
Frequency of intake of the different food categories in patients with and without muscle atrophy
The percentage of patients with and without muscle atrophy who assume never/rarely and regularly the different food categories.
Time frame: Through study completion, an average of 1 year.
Inflammatory serum markers
Mean ± standard error of the mean, median, and min-max range of circulating IL-6, IL-8, TNF-α in patients
Time frame: Through study completion, an average of 1 year.
Serum markers of bone metabolism
Mean ± standard error of the mean, median, and min-max range of circulating FGF-21, GDF15, ST2 in patients
Time frame: Through study completion, an average of 1 year.
Characterization of gut microbiota
The "Next Generation Sequencing" technology will be employed to characterize the overall microbiome profile in stool samples, and bioinformatics used to assess alpha-diversity (ecological diversity of a single sample according to the number of different taxa and their relative abundances) and beta-diversity (differences in microbial community composition between individuals).
Time frame: Through study completion, an average of 1 year.
Started Nov 2020 (actual). Primary completion is estimated for Dec 2026, 73 months after the start.
Of 52 non-industry observational studies under Osteoarthritis, Hip, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 59. This study's planned 73 months is above that.
Counting every sponsor, half of 81 studies reached it within 53 months; a quarter within 13 and three quarters within 113.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.